Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials

被引：0
|
作者：
You, B.
Gan, H. K.
Pond, G. R.
Chen, E. X.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Austin Hosp, Melbourne, Vic 3084, Australia
[3] McMaster Univ, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Independent central review of progression in randomized phase II/III oncology trials: Is it needed?
    Wu, W.
    Lin, L. I.
    Sargent, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Factors associated with publication of randomized phase III cancer trials in journals with a high impact factor
    Tang, P. A.
    Pond, G. R.
    Welch, S.
    Chen, E. X.
    CURRENT ONCOLOGY, 2014, 21 (04) : E564 - E572
  • [33] Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
    Paparo, J.
    Zumstein, L.
    Notarnicola, S.
    Marandino, L.
    Perrone, F.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S950 - S951
  • [34] Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
    Suji Udayakumar
    Sasha Thomson
    Albiruni R. Abdul Razak
    Kelvin K. W. Chan
    Targeted Oncology, 2022, 17 : 665 - 674
  • [35] Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
    Udayakumar, Suji
    Thomson, Sasha
    Razak, Albiruni R. Abdul
    Chan, Kelvin K. W.
    TARGETED ONCOLOGY, 2022, 17 (06) : 665 - 674
  • [36] Primary Endpoints in Current Phase II/III Trials for Alzheimer Disease A Systematic Survey of Trials Registered at ClinicalTrials.gov
    Takeshima, Nozomi
    Ishiwata, Keita
    Sozu, Takashi
    Furukawa, Toshi A.
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2020, 34 (01): : 97 - 100
  • [37] Influence of trial registration on reporting quality of randomized trials: Study from highest ranked journals
    Reveiz, L.
    Cortes-Jofre, M.
    Asenjo Lobos, C.
    Nicita, G.
    Ciapponi, A.
    Garcia-Dieguez, M.
    Tellez, D.
    Delgado, M.
    Sola, I.
    Ospina, E.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (11) : 1216 - 1222
  • [38] Methods for Missing Data Handling in Randomized Clinical Trials With Nonnormal Endpoints With Application to a Phase III Clinical Trial
    Fan, Chunpeng
    Zhang, Donghui
    Wei, Lynn
    Koch, Gary
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (02): : 179 - 193
  • [39] Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis
    Rodriguez, Joel Veas
    Prieto, Ana
    Vilaprinyo, Ester
    Bonet, Marta
    Diez, Marc
    Salud, Antonieta
    Montal, Robert
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 201
  • [40] Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
    Gan, H. K.
    You, B.
    Pond, G. R.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345